Tacrolimus Envarsus Xr denied due to quantity / dose limits by Cigna?

Cigna's specific coverage criteria for tacrolimus envarsus xr are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Applied a Quantity Limit to Tacrolimus Envarsus XR

A quantity-limit denial means Cigna's system approved Envarsus XR but capped the dispensed amount — typically based on days supply per fill, units per fill, or units per month — at a level lower than what was prescribed. Quantity limits for extended-release tacrolimus are common and are usually based on standard dosing assumptions embedded in the plan's pharmacy benefit manager rules. When a prescribed regimen falls outside those assumptions, an exception is needed.

Quantity-limit exceptions for transplant immunosuppressants are among the more straightforward to win when the prescriber documents the clinical basis for the prescribed regimen. The key is showing that the prescribed quantity reflects the patient's actual therapeutic needs as determined by the treating transplant team.

## Your Federal Appeal Rights

• Quantity-limit exception / internal appeal: File within the window on your denial notice. Cigna must respond within applicable regulatory timeframes (typically 30 days pre-service, 60 days post-service for standard appeals).
• External review (ACA §2719): If the internal appeal is denied, non-grandfathered plans must offer independent external review, generally within approximately four months of the final internal denial.
• ERISA §503: Employer-plan members have the right to a full-and-fair review, including the specific clinical and policy basis for the quantity restriction.
• Expedited review: If the quantity limit is causing a gap in immunosuppression, expedited review (typically 72 hours) is available and appropriate.

## What to Gather

1. Prescription and dispensing records: The exact quantity prescribed, the days supply intended, and the quantity dispensed after the limit was applied. 2. Cigna's quantity-limit policy: Request or download the specific policy to understand what limit was applied and what documentation is required for an exception. 3. Prescriber documentation: Your transplant physician should explain why the prescribed quantity is medically necessary for your specific regimen, referencing the FDA-approved prescribing information for Envarsus XR, which specifies approved dosing ranges and adjustment guidance. 4. Clinical record: Lab values and clinic notes showing the basis for the current prescribed regimen, including any dose adjustments made by your transplant team.

## Criteria-Mapping Structure

Obtain the quantity-limit exception criteria from Cigna's pharmacy benefit documentation. Then match each criterion to your documentation:

| Quantity-Limit Exception Criterion | Supporting Documentation | |---|---| | [Criterion from policy] | [Prescriber letter / clinic note / lab date] |

A brief, focused appeal that explains the clinical basis for the prescribed quantity — anchored to the FDA label's dosing guidance and signed by the transplant physician — is usually sufficient to overturn a quantity-limit denial where the prescription is clinically appropriate.